Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wish it was RIP for all the negative goobers who keep posting meaningless inanities like “rip” for every stock they don’t own.
Don’t you?
They need OTC markets to unlock the upload for the 10K or NT
They could.maybe they want to the expert market and when this gets to 0.0001 they will release fillings and insiders get cheap shares
Could they be manipulating this as low as possible before they file the merger? So will get less.value?
They should have been doing that months / years ago lol
LEAS could also be communicating with OTC Markets
Got to love the non communication from company
I think this is a selloff before the end of the grace period and then likely expert market.
Expert market will lower the price significantly, but if it all goes through as hoped (and that's questionable) then EM doesn't matter. It's a big gamble though.
They invested to much time and money on this. It will comeback
No shit.. why did they approve merger if their plan was to fuck its shareholders..fucking bs
At this moment it is not any manipulation but pure sell off.Somethink stink.We shall see.
I laugh at the MASSIVE manipulation and getting ready to help myself to some freebies. Hard to know when to get them but it will happen so manipulate away.
I'll be here to fill my boots if they bring it lower.
This is going to be pushed down for some people in behind to buy it cheap.
Wonder why its not running i mean merger is approved… wtf?
Yes I know but I thought some big buying volume.This is volume just for speculations.
Do you not have level 2, 400k smack 510k buys 132k sells
Still not buyers of this stock.What is going on next ??? the merger is going to be by June ?
Thanks for sharing..
LEAS
Trading was temporarily halted for "RWOD" at 09:04 AM with a stated reason of "LULD pause."https://www.marketbeat.com/market-data/trading-halts/
Filling buys at 52, they know what's coming
Sorry to hear this, I'll help however I can
I can't help to think if we listened to him back when he stickied his own post back in August. We would be kicking ourselves so we certainly shouldn't be listening to him now.
Thanks Huggy but we are just here to trade the trade.
Good contribution as per usual.
The bleeding will continue today! Close in the .004s!
Back in February this year, the doctor posted this on Yahoo board. He sounds sincere and even mentioned for the Leas shareholders. I don't sense any ill intent from the post:
Thomas,
ANEW has been working diligently, day-by-day, week-by-2week, month-by-month since May of 2023 to bring value and additional assets into the company. We cleared SEC comments last week and the SPAC's (Redwoods) attorneys (Loeb&Loeb) are working on the Redwoods shareholder meeting, and so on. I am told that we will be completing the M&A in March and likely trading under our Nasdaq symbol, "WENA" by the end of March, God willing. I want to thank the shareholders of the old defunct shell, Strategic Asset Leasing, and the investors who have been putting money into ANEW MEDICAL for their patience and financial support. The S-4 filed by the SPAC, Nasdaq:RWOD, further explains the process going forward. We at ANEW are looking forward to being listed on Nasdaq, a major global market for pharma and biotechnology companies like ANEW, and the listing providing us a vehicle and offering structure for rounds of financing needed to take drugs from discovery to market approval.
That's why I keep repeating they have never said how they'll distribute those shares. If, for example, they distribute them to the former shareholders of ANEW, the common shareholders of LEAS will get nothing (or very little).
RWOD is about to be diluted a lot, too, and since it looks like they'll be distributing just about all their cash to the shareholders who have chosen to redeem their stock, they'll have to sell stock to raise money to do anything.
Yea, the preferred share B converts to about 500m common shares. So if it combines with the current 1 billion common shares..total common shares are 1.5B shares.
It will still provide a decent return to the shareholders
They have never said how those shares were to be distributed.
LEAS had planned a 1 for 2500 RS of the common stock followed by the conversion of the preferred B's held by the owners of ANEW (pre-RM) into just over 40M shares of stock. The RS would reduce the O/S to a little over 400K shares, meaning their intent was for the owners of ANEW to own 99% of the equity in LEAS after the RM. Makes sense, since no LEAS bagholder had given them a plug nickel for the growth of ANEW, that was the private investors.
Sometime after the business combination was announced, Sinkule put in that they no longer needed the RS, and he's right. They can distribute those RWOD shares any way they want to, and considering that Sinkule just took about 23% of them, I'd expect those Preferred B holders to get the vast majority of the remaining. Sinkule has complete control over the distribution, since he owns the vote.
then the remaining 4.6m shares belong to the shareholders. That sounds okay, right?
Clear as day the dr manipulating the stock so he can help out insiders his friends family
Page 26...
He gets 1.4M of the 6M shares.
Fear-mongering duped some out of their shares. Too bad y'all succumbed.
Dang, I saw a bid/ask spread of $.0028/.0039. Knew I should’ve put in a bid in the low 30’s. Nice rebound.
Right back to 65, lol, LEAS obviously filing NT
He can't you moron, etf
I love how you all get duped out of your shares. The scammers are the ones scamming you out of your shares.
Where does it say?
Its done now
Medical product development and commercialization. The Company recently acquired five generic oncology drugs approved and manufactured in Germany and they plan to gain approval for these drugs in the US in 2023. The Company is preparing for a pivotal Phase 3 study of an anti-cancer antibody product that is highly similar to Genentech/Roche's brand name Avastin (bevacizumab), the Company has licensed a needle-free jet injector for drug delivery, and the Company is in the pre-clinical stages of development of a gene therapy product candidate based on the delivery of a human alpha-Klotho gene and protein to prevent and/or treat neurodegenerative diseases such as Alzheimer's and Lou Gehrig's disease (ALS). Other product candidates will stem from these platform technologies of pharmaceuticals, biologics, and gene therapy.
The Company's medical R&D facilities are in the U.S. (near the University of Nebraska Medical Center, Omaha, Nebraska) and in Barcelona, Spain (Autonomous Universitat de Barcelona). Each R&D facility is comprised of over 4,000 sq ft of R&D and office space, currently leased and equipped with research equipment, incubators, tissue culture facilities for production of plasmid DNA, HEPA-filtered hoods for aseptic handling, and testing equipment (PCR, spectrophotometers, microscopes, etc). The generic oncology drugs are manufactured in Germany. With future funding, the Company plans to acquire or build a GMP manufacturing facility to supply novel plasmid DNA ("transgenes") to be used in gene therapy programs, to provide contract manufacturing revenue, and for commercial product manufacturing.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |